Table 2:
(A) Table showing the available clinical characteristics of 150 patients of the TCGA study [Prostate adenocarcinoma (MSKCC, cancer cell 2010)] extracted from cBioportal. (B) Table showing the associations between the mRNA expression levels of Nodal and clinical characteristics indicating that Nodal expression is significantly upregulated with higher (9) compared to lower Gleason score (6–7).
| Characteristics | No. of patients (N=150) | % |
|---|---|---|
| Age [years] | Unknown | |
| Gleason score | 41 | 27.33 |
| 6 | 76 | 50.67 |
| 7 | 11 | 7.33 |
| 8 | 11 | 7.33 |
| 9 | 0 | 0 |
| 10 | 11 | 7.33 |
| NA | ||
| T stage [pT] | 80 | 53.33 |
| T1 | 58 | 38.67 |
| T2 | 6 | 4 |
| T3 | 1 | 0.67 |
| T4 | 5 | 3.33 |
| NA | ||
| N stage [pN] | Unknown | |
| M stage [pM] | Unknown | |
| Survival status | Unknown | |
| Characteristics (Number of patients) | Mean Nodal mRNA expression | P value |
| Gleason score | 6.15 | 0.0062 (GS 6–7 vs.GS 9) |
| 6–7 (117) | 6.19 | |
| 8 (11) | 6.52 | |
| 9–10 (11) | ||
| T stage [pT] | 6.184 | 0.5592 |
| T1–2 (138) | 6.104 | |
| T3–4 (7) | ||
| Disease free Survival | 6.22 | 0.2557 |
| Median | 6.15 | |
| ≤ 45.37 mths (70) | ||
| > 45.37 mths (70) | ||
| Overall survival | Unknown | |